Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Myeloma CAR-T update with Nina Shah

Nina Shah • 8 Jun 2020
EHA 2020
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel Orvacabtagene autoleucel
EVOLVE KarMMa

Nina Shah, MD, of the University of California, San Francisco, CA, discusses the advent of BCMA CAR-T therapy in multiple myeloma, highlighting data from the KarMMA trial (NCT03361748), updates with ciltacabtagene autoleucel (cilta-cel), and orvacabtagene autoleucel (orva-cel; NCT03430011). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nina Shah

19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
1:28
NKTR-255 in multiple myeloma and NHL
Nina Shah • 10 Dec 2021
2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021
2:06
Subanalysis of the KarMMa Trial: Predicting complete response to CAR-T in multiple myeloma
Nina Shah • 10 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals